Bayer, Evotec Ink Agreement to Develop PCOS Treatments
2020年1月9日 - 4:16PM
Dow Jones News
By Carlo Martuscelli
Bayer AG (BAYN.XE) said Thursday that it will partner with
Evotec SE (EVT.XE) to develop therapies for polycystic ovary
syndrome, a common hormone disorder that affects women.
Under the terms of the five-year collaboration agreement, German
drug discovery company Evotec is eligible for 16.5 million euros
($18.4 million) in research payments as well as more than EUR330
million in milestone payments, plus royalties generated from sales
of treatments that enter the market.
Bayer and Evotec will collaborate in the early development
stage, while Bayer will be responsible for clinical trials and
commercialization, it said.
The two companies have previously signed collaboration deals to
develop drugs targeting endometriosis and kidney disease.
Write to Carlo Martuscelli at carlo.martuscelli@wsj.com;
@carlomartu
(END) Dow Jones Newswires
January 09, 2020 02:01 ET (07:01 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
Bayer (TG:BAYN)
過去 株価チャート
から 3 2024 まで 4 2024
Bayer (TG:BAYN)
過去 株価チャート
から 4 2023 まで 4 2024
